Search Results

• • 12 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment

  Authors:Meral Beksac, Mutlu Arat, Hamdi Akan, Haluk Koc, Osman Ilhan, and Muhit OzcanFrom:Cancer (Vol. 89, Issue 7) Peer-Reviewed

  Oct. 1, 2000 Article

   Citation Only

• Daratumumab, bortezomib, and dexamethasone for multiple myeloma

  Authors:Pieter Sonneveld, Andrew Spencer, Ming Qi, Vania Hungria, Ivan Spicka, Meral Beksac, et al.From:The New England Journal of Medicine (Vol. 375, Issue 8) Peer-Reviewed

  Aug. 25, 201646 words Report

   Citation Only

• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

  Authors:Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, et al.From:The New England Journal of Medicine (Vol. 385, Issue 1) Peer-Reviewed

  July 1, 202150 words Report

   Citation Only

• Continuous Lenalidomide treatment for newly diagnosed multiple myeloma

  Authors:Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, et al.From:The New England Journal of Medicine (Vol. 366, Issue 19) Peer-Reviewed

  May 10, 201241 words Clinical report

   Citation Only

• Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  Authors:Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Herve Avet-Loiseau, Tomer M. Mark, Ivan Spicka, et al.From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-Reviewed

  Aug. 20, 20204,813 words Report 1390LBackground Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus...

• The shaping of modern human immune systems by multiregional admixture with archaic humans

  Authors:Laurent Abi-Rached, Matthew J. Jobin, Subhash Kulkarni, Alasdair McWhinnie, Klara Dalva, Loren Gragert, et al.From:Science (Vol. 334, Issue 6052) Peer-Reviewed

  Oct. 7, 2011129 words Author abstract, Rep...

   Abstract Only

• Elotuzumab therapy for relapsed or refractory multiple myeloma

  Authors:Sagar Lonial, Jessica Katz, Eric Bleickardt, Morio Matsumoto, Jesus San-Miguel, Anil Singhal, et al.From:The New England Journal of Medicine (Vol. 373, Issue 7) Peer-Reviewed

  Aug. 13, 201579 words Report

   Citation Only

• Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival

  Authors:Kemal Beksac, Meral Beksac, Klara Dalva, Ergun Karaagaoglu, and M. Bulent TirnaksizFrom:PLoS ONE (Vol. 10, Issue 7) Peer-Reviewed

  July 16, 20154,946 words Article 1330LApproximately 30 % of patients with stage II/III colorectal cancer develop recurrence following surgery. How individual regulation of host mediated anti-tumor cytotoxicity is modified by the killer-cell...

• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

  Authors:Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, et al.From:The Lancet (Vol. 393, Issue 10168) Peer-Reviewed

  Jan. 19, 20191,264 words Article

   Abstract Only

• [beta]-catenin mutations in acute myeloid leukemia.

  Authors:Buket Gunes, Tulin Ozkan, Aynur Gurel, Yalda Hekmatshoar, Meral Beksac, and Asuman SungurogluFrom:The Egyptian Journal of Haematology (Vol. 45, Issue 2) Peer-Reviewed

  April-June 20202,991 words Article 1550LByline: Buket. Gunes, Tulin. Ozkan, Aynur. Gurel, Yalda. Hekmatshoar, Meral. Beksac, Asuman. Sunguroglu Background Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by uncontrolled...

• HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA.

  Authors:Fengjie Jiang, Xiaozhu Tang, Chao Tang, Zhen Hua, Mengying Ke, Chen Wang, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  Apr. 1, 20212,094 words Article 1880LN6-methyladenosine (m6A) modification is the most prevalent modification in eukaryotic RNAs while accumulating studies suggest that m6A aberrant expression plays an important role in cancer. HNRNPA2B1 is a m6A reader...

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  Authors:Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, et al.From:The Lancet (Vol. 394, Issue 10214) Peer-Reviewed

  Dec. 7, 20191,124 words Report

   Abstract Only